GHK-Cu peptide for hair growth: real science or TikTok hype?
Quick answer
Brenda is using AHK-Cu (copper tripeptide-3) topically to address hair thinning she attributes to nutrient depletion from GLP-1 receptor agonist use, a pattern consistent with telogen effluvium. While copper peptides have documented mechanisms related to follicle cycling and anagen phase support, AHK-Cu specifically lacks robust independent human clinical trial data for hair density. The DIY mixing approach raises concentration and stability concerns that formulated products with established dosing do not.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @brenda.kircher actually say?
Brenda is dissolving one gram of AHK-Cu (copper tripeptide-3) powder into The Ordinary's Multi-Peptide Serum for Hair Density and applying it topically. Her core claims: the peptide "helps stimulate hair growth, boost circulation to the scalp, and reduce hair loss," and the water-soluble powder blends safely with the water-based serum. She also connects her hair thinning to GLP-1 medication use and nutrient deficiency, framing this DIY mix as her recovery plan.
She is not claiming this cures anything. She is presenting it as a supportive, topical experiment. That framing is actually more honest than most hair content on TikTok, and it matters when evaluating what she got right versus wrong.
Does the science back this up?
Partially, yes, but the evidence base is thinner than her enthusiasm suggests. AHK-Cu is a real peptide with real mechanism data, but robust human clinical trials are scarce.
The peptide GHK-Cu (copper tripeptide-1) has the stronger research record for hair. Uno et al. (1987, Journal of Investigative Dermatology) showed topical copper peptides extended the anagen (growth) phase in animal models. Pickart and Margolina (2018, Biomedicines) reviewed GHK-Cu's role in activating hair follicle proteins and noted anti-inflammatory signaling that could theoretically reduce follicle miniaturization. AHK-Cu specifically is less studied than GHK-Cu. A 2018 patent filing by Procter and Gamble cited AHK-Cu for follicle stimulation, and The Ordinary's own product already contains it, but peer-reviewed independent clinical trials on AHK-Cu alone for hair density in humans are not currently available in the published literature.
Circulation-boosting claims at the scalp level have some support from vasodilatory peptide research generally, but attributing this specifically to AHK-Cu applied topically requires more evidence than exists right now.
What did they get wrong (or right)?
The compatibility claim is correct. AHK-Cu is water-soluble and The Ordinary serum is water-based. Mixing them is not chemically reckless. Credit where it is due.
The dosing is where things get murky. She is adding one gram of raw AHK-Cu powder to a commercial serum. One gram is a significant quantity. The Ordinary's serum already contains AHK-Cu at a formulated concentration. Adding raw powder on top creates an unknown final concentration with no stability testing behind it. Peptide concentration matters. Too little does nothing. Too much in an uncontrolled mix may degrade before it reaches the follicle or could cause scalp irritation. There is no published guidance on safe topical AHK-Cu concentrations for DIY use.
The GLP-1 hair thinning connection is actually well-placed. Telogen effluvium, a temporary shedding triggered by nutritional stress, is a documented side effect pattern seen with rapid weight loss and GLP-1 receptor agonist use. Dowd et al. (2024, JAMA Dermatology) noted increased alopecia reports among semaglutide users. Addressing the nutritional deficit is the medically sound first step, which she acknowledges. Using a topical peptide on top of that is speculative but not harmful in principle.
What should you actually know?
If your hair is thinning from GLP-1-related nutrient deficiency, the root cause is systemic, not topical. No serum, peptide, or DIY blend fixes a ferritin deficiency or protein shortfall at the scalp surface. Getting bloodwork done, specifically ferritin, zinc, and total protein, is a more evidence-supported first move than mixing powders.
That said, topical copper peptides are not snake oil. The mechanistic case for follicle support is real, even if the human clinical data for AHK-Cu specifically is preliminary. If you want to try something like this, a formulated product with known concentrations is a safer starting point than adding raw powder to an existing product.
- AHK-Cu has plausible biological mechanisms for follicle support but lacks independent human clinical trial data specific to hair density outcomes.
- DIY peptide mixing introduces unknown concentrations and stability risks that formulated products do not have.
- GLP-1-related hair thinning is real, but it is primarily a systemic nutritional issue, not a scalp surface issue.
- If you are on a GLP-1 medication and experiencing shedding, talk to a clinician about nutrient repletion before spending money on topical peptides.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
GHK-Cu (Copper Peptide) access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For GHK-Cu peptide for hair growth: real science or TikTok hype?, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
GHK-Cu (Copper Peptide) is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Claim path
Keep researching this ghk-cu video claims cluster
Best for searchers checking whether GHK-Cu beauty and recovery claims match the evidence base.
Claim verdict
The useful answer behind this video
Claim being checked
Brenda is using AHK-Cu (copper tripeptide-3) topically to address hair thinning she attributes to nutrient depletion from GLP-1 receptor agonist use, a pattern consistent with telogen effluvium.
FormBlends verdict
Brenda is using AHK-Cu (copper tripeptide-3) topically to address hair thinning she attributes to nutrient depletion from GLP-1 receptor agonist use, a pattern consistent with telogen effluvium. While copper peptides have documented mechanisms related to follicle cycling and anagen phase support, AHK-Cu specifically lacks robust independent human clinical trial data for hair density. The DIY mixing approach raises concentration and stability concerns that formulated products with established dosing do not.
Patient-safe next step
Compare the claim with the GHK-Cu (Copper Peptide) guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Brenda is using AHK-Cu (copper tripeptide-3) topically to address hair thinning she attributes to nutrient depletion from GLP-1 receptor agonist use, a pattern consistent with telogen effluvium. While copper peptides have documented mechanisms related to follicle cycling and anagen phase support, AHK-Cu specifically lacks robust independent human clinical trial data for hair density. The DIY mixing approach raises concentration and stability concerns that formulated products with established dosing do not.
- AHK-Cu (copper tripeptide-3) has plausible follicle-support mechanisms, but peer-reviewed human clinical trials specific to AHK-Cu for hair density are not yet available in published literature.
- GHK-Cu has the stronger published evidence base for hair: Uno et al. (1987, Journal of Investigative Dermatology) demonstrated anagen phase extension with topical copper peptides in animal models.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- GHK-Cu (Copper Peptide) decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the GHK-Cu (Copper Peptide) guide, cost path, safety notes, and provider review before acting.
Review GHK-Cu (Copper Peptide)What You'll Learn
- AHK-Cu (copper tripeptide-3) has plausible follicle-support mechanisms, but peer-reviewed human clinical trials specific to AHK-Cu for hair density are not yet available in published literature.
- GHK-Cu has the stronger published evidence base for hair: Uno et al. (1987, Journal of Investigative Dermatology) demonstrated anagen phase extension with topical copper peptides in animal models.
- GLP-1-related hair thinning is real and documented: Dowd et al. (2024, JAMA Dermatology) noted increased alopecia reports among semaglutide users, consistent with telogen effluvium from nutritional stress.
- Telogen effluvium from nutrient depletion is a systemic problem. Topical peptides do not correct low ferritin, zinc deficiency, or inadequate protein intake, which are the primary drivers.
- Adding raw peptide powder to a formulated serum that already contains that peptide creates an unknown concentration and bypasses the stability testing that regulated formulations undergo.
- Formulated products with established concentrations are a safer starting point than DIY powder mixing for anyone without access to proper compounding equipment and testing.
- If you are experiencing hair thinning on a GLP-1 medication, bloodwork including ferritin and zinc panels is a more evidence-supported first step than any topical intervention.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Brenda Kircher | Creator · TikTok creator
12.6K views on this video
#hairgrowth #hairthinning #copperpeptides #diyhaircare #creatorsearchinsights
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Brenda Kircher | Creator, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.